Immuneering (IMRX) Capital Expenditures (2020 - 2024)
Historic Capital Expenditures for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to $9356.0.
- Immuneering's Capital Expenditures fell 9452.6% to $9356.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $84875.0, marking a year-over-year decrease of 7523.68%. This contributed to the annual value of $84875.0 for FY2024, which is 7523.68% down from last year.
- Immuneering's Capital Expenditures amounted to $9356.0 in Q4 2024, which was down 9452.6% from $5268.0 recorded in Q3 2024.
- In the past 5 years, Immuneering's Capital Expenditures registered a high of $393134.0 during Q3 2022, and its lowest value of $5268.0 during Q3 2024.
- Moreover, its 5-year median value for Capital Expenditures was $35125.5 (2024), whereas its average is $70808.4.
- As far as peak fluctuations go, Immuneering's Capital Expenditures skyrocketed by 336495.68% in 2022, and later plummeted by 9452.6% in 2024.
- Quarter analysis of 5 years shows Immuneering's Capital Expenditures stood at $38058.0 in 2020, then crashed by 65.7% to $13052.0 in 2021, then skyrocketed by 430.97% to $69302.0 in 2022, then soared by 146.63% to $170918.0 in 2023, then tumbled by 94.53% to $9356.0 in 2024.
- Its last three reported values are $9356.0 in Q4 2024, $5268.0 for Q3 2024, and $32773.0 during Q2 2024.